Marcaine (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on nerve fibers, preventing the rapid influx of sodium ions needed for depolarisation. This stops the initiation and conduction of nerve impulses, producing a reversible loss of sensation in the area where it is administered.

The specific dose of Marcaine is determined by the prescribing clinician based on the procedure, patient characteristics, and regulatory guidelines. Healthcare professionals calculate the appropriate volume and concentration to achieve effective analgesia while minimizing toxicity.

Safety data for bupivacaine in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use is generally reserved for situations where the benefit outweighs potential risk, and it should be administered only under specialist supervision.

To order Marcaine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with shorter‑acting agents such as lidocaine, bupivacaine provides a longer duration of analgesia, making it preferable for procedures requiring extended pain control. However, its higher potency also demands careful dosing and monitoring to avoid cardiovascular or central nervous system toxicity.

Marcaine should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the solution from direct light and moisture, and keep it out of reach of children. Do not freeze the product.

Marcaine is administered by a trained healthcare professional via epidural catheter, direct infiltration into tissues, or intra‑articular injection. The route chosen depends on the clinical indication, and the injection technique follows standard aseptic and safety protocols.

The most serious risks include cardiovascular toxicity (arrhythmias, cardiac arrest) and central nervous system toxicity (seizures, respiratory depression). Early recognition of symptoms and immediate supportive measures are essential to mitigate these potentially life‑threatening events.

Marcaine is contraindicated in patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, and in individuals with significant cardiac conduction abnormalities or uncontrolled epilepsy. Caution is also advised for patients with severe hepatic impairment.